Old Web
English
Sign In
Acemap
>
authorDetail
>
Marion Carrigan
Marion Carrigan
Merck & Co.
Endometrial cancer
Pembrolizumab
Medicine
Carcinoma
Cohort
3
Papers
234
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study
2018
Obstetrical & Gynecological Survey
Patrick A. Ott
Yung-Jue Bang
Dominique Berton-Rigaud
Elena Elez
Michael J. Pishvaian
Hope S. Rugo
Igor Puzanov
Janice M. Mehnert
Kyaw Lwin Aung
Juanita Lopez
Marion Carrigan
Sanatan Saraf
Mei Chen
Jean-Charles Soria
Show All
Source
Cite
Save
Citations (5)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
2017
Journal of Clinical Oncology
Patrick A. Ott
Yung-Jue Bang
Dominique Berton-Rigaud
Elena Elez
Michael J. Pishvaian
Hope S. Rugo
Igor Puzanov
Janice M. Mehnert
Kyaw Lwin Aung
Juanita Lopez
Marion Carrigan
Sanatan Saraf
Mei Chen
Jean-Charles Soria
Show All
Source
Cite
Save
Citations (209)
Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.
2016
Journal of Clinical Oncology
Patrick A. Ott
Yung-Jue Bang
Dominique Berton-Rigaud
Elena Elez
Michael J. Pishvaian
Hope S. Rugo
Igor Puzanov
Mark A. Morgan
Janice M. Mehnert
Kyaw Lwin Aung
Marion Carrigan
Sanatan Saraf
Mei Chen
Jean-Charles Soria
Show All
Source
Cite
Save
Citations (20)
1